Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B MAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme

NCT00509301 is registered in ClinicalTrials.gov with Peregrine Pharmaceuticals as lead sponsor.

NCT NCT00509301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00509301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B MAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme
Lead sponsor
Peregrine Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2006
Completion date
March 31, 2010
Enrollment
12 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma multiforme